Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy.
Epigenetic mechanisms, including DNA methylation and histone post-translational modifications (PTM), have been known to regulate chromatin structure and lineage-specific gene expression during cardiovascular development and disease. However, alterations in the landscape of histone PTMs and their contribution to the pathogenesis of incurable cardiovascular diseases such as pulmonary hypertension (PH) and associated right heart failure (RHF) remains largely unexplored. This review focusses on the studies in PH and RHF that investigated the gene families that write (histone acetyltransferases, HATs), read (bromodomain-containing proteins, BRDPs) or erase (histone deacetylases, HDACs and Sirtuins, SIRT) acetyl moieties from the ε-amino group of lysine residues of histones and non-histone proteins. Analysis of cells and tissues isolated from the in vivo preclinical models of PH and human pulmonary arterial hypertension (PAH) not only confirmed significant alterations in the expression levels of multiple HDACs, SIRT1, SIRT3, and BRD4 proteins but also demonstrated their strong association to proliferative, inflammatory and fibrotic phenotypes linked to the pathological vascular remodeling process. Due to the reversible nature of post-translational protein acetylation, the therapeutic efficacy of numerous small-molecule inhibitors (Vorinostat, Valproic acid, Sodium butyrate, Mocetinostat, Entinostat, Tubastatin A, Apabetalone, JQ1, Resveratrol) have been evaluated in different pre-clinical models of cardiovascular disease, which revealed the promising therapeutic benefits of targeting histone acetylation pathways in the attenuation of cardiac hypertrophy, fibrosis, left heart dysfunction, PH and RHF. This review also emphasizes the need for deeper molecular insights into the contribution of epigenetic changes to PH pathogenesis, and therapeutic evaluation of isoform-specific modulation in ex vivo and in vivo models of PH and RHF.